B7-H3 NIR Imaging for Osteosarcoma Surgery

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jan 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique using a special probe called B7-H3-IRDye800CW to help surgeons remove all of the osteosarcoma (a type of bone cancer) during surgery. The goal is to ensure that no cancer cells are left behind, which can lead to the cancer coming back. This probe targets a specific protein that is often found in higher amounts in osteosarcoma, making it easier for doctors to see where the tumor is during surgery. The trial will track how effective this technique is in removing the tumor completely and whether it helps reduce the chance of the cancer returning over the next two years.

To participate in this trial, patients need to be between 18 and 60 years old and have a confirmed diagnosis of osteosarcoma in their limbs without having had any previous tumor surgery. They should also be in good overall health and able to give consent to participate. If you join the trial, you will receive this new imaging agent before your surgery, and the medical team will monitor its safety and effectiveness throughout the process. This study is currently looking for volunteers, and it aims to improve the surgical treatment of osteosarcoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histologically confirmed osteosarcoma of the limbs.
• • 2. the patients has not undergone tumor resection.
• • 3. Age between 18 and 60 years old.
• • 4. No prior systemic treatment for osteosarcoma.
• • 5. Measurable disease as assessed by imaging studies (e.g., MRI, CT).
• • 6. Adequate bone marrow, liver, and renal function.
• • 7. Written informed consent obtained from the patient.
• Exclusion Criteria:
• • 1. History of other malignancies within the past 5 years.
• • 2. Pregnancy or lactation.
• • 3. Known hypersensitivity to any component of the B7H3-based NIR imaging agent.
• • 4. Uncontrolled intercurrent illness that would preclude safe study participation.
• • 5. Prior radiation therapy to the target lesion.
• • 6. Any medical condition that would compromise the patient's ability to undergo surgery or comply with study procedures.
• • 7.Patients not able to sign the Informed Consent.